Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juni 2024

Genmab — Juni 2024

Planlagt Fastgjort Låst Flyttet Genmab
946 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • G Offline
    G Offline
    GeorgeBest
    wrote on sidst redigeret af
    #8

    Combining acasunlimab with pembrolizumab showed improved efficacy and safety when pembrolizumab was administered with a 6-week dosing regimen compared to a 3-week regimen. Interestingly, liver-related events were also less frequent with the 6-week https://x.com/onco_park/status/1796947082323910739?s=61&t=Ry4q9LC1jDgQzC__0QIEPg
    pembrolizumab dosing.

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #9

      RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer progression-free survival versus osimertinib in first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-plus-lazertinib-is-the-only-chemotherapy-free-regimen-showing-longer-progression-free-survival-versus-osimertinib-in-first-line-treatment-of-patients-with-high-risk-egfr-mutated-non-small-c

      1 Reply Last reply
      0
      • L Offline
        L Offline
        lahn1
        wrote on sidst redigeret af
        #10

        God morgen ! og tak for de positive links

        1 Reply Last reply
        0
        • M Offline
          M Offline
          MagnusHB
          wrote on sidst redigeret af
          #11

          Hvad er folks forvetninger til aktiekursen imorgen? P
          å baggrund af de nye dataer der er kommet ud.

          1 Reply Last reply
          0
          • V Offline
            V Offline
            Vitus
            wrote on sidst redigeret af
            #12

            Jeg tænker den falder….det plejer den ved positive nyheder…..eller fordi de er mindre positive end forventet…

            1 Reply Last reply
            0
            • L Offline
              L Offline
              lahn1
              wrote on sidst redigeret af
              #13

              Kursen skal op op op ?

              1 Reply Last reply
              0
              • W Offline
                W Offline
                w
                wrote on sidst redigeret af
                #14

                spørgsmålet er vel om disse opdaterede data er bedre end dem vi så for et par uger siden, hvor der blev kvitteret med minus 5%

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #15

                  DoR og OS for acasunlimab ser vel ganske gode ud - og Rybrevant kører derudaf, så op burde være takten, men med Genmab ved man jo aldrig. Epco betyder nok også mere…..

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #16

                    Lorlatinib ser ud til at være en væsentlig konkurrent https://www.bt.dk/sundhed/forskere-begejstrede-ny-behandling-mod-lungekraeft-kan-vaere-paa-vej

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #17

                      Vi må finde data et sted.

                      1 Reply Last reply
                      0
                      • SolsenS Offline
                        SolsenS Offline
                        Solsen
                        wrote on sidst redigeret af
                        #18

                        Måske ikke samme patientgruppe. Thu Guadian skriver “The participants all had ALK-positive non-small cell lung cancer”

                        1 Reply Last reply
                        0
                        • SolsenS Offline
                          SolsenS Offline
                          Solsen
                          wrote on sidst redigeret af
                          #19

                          Men imponerende 5 årig overlevelse på +60 % vs -10% i kontrolgruppen.

                          1 Reply Last reply
                          0
                          • L Offline
                            L Offline
                            lossen
                            wrote on sidst redigeret af
                            #20

                            AI (Gemini) fortæller mig, at ALK-positiv lungekræft er en sjælden type lungekræft, som kun udgør 3-7% af alle lungekræfttilfælde

                            1 Reply Last reply
                            0
                            • SolsenS Offline
                              SolsenS Offline
                              Solsen
                              wrote on sidst redigeret af
                              #21

                              Tak. Men virkelig imponerende OS.

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #22

                                En overraskende forbedring af effekt og reduktion af bivirkninger på sc versionen af amivantamab. Det tegner godt !

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #23

                                  ASCO 2024 – acasunlimab impresses on overall survival https://www.oncologypipeline.com/apexonco/asco-2024-acasunlimab-impresses-overall-survival

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #24

                                    ENDO 2024
                                    Teprotumumab Gives Lasting Relief from Thyroid Eye Disease https://www.medscape.com/viewarticle/teprotumumab-gives-lasting-relief-thyroid-eye-disease-2024a1000ab9?form=fpf

                                    1 Reply Last reply
                                    0
                                    • Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktør
                                      wrote on sidst redigeret af
                                      #25

                                      Godmorgen 🙂

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        ProinvestorNEWS
                                        wrote on sidst redigeret af
                                        #26

                                        Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Re https://proinvestor.com/investornyt/1167767/preliminary-analysis-of-data-evaluating-investigational-epcoritamab-duobody-cd3xcd20-combination-demonstrates-95-overall-re

                                        1 Reply Last reply
                                        0
                                        • B Offline
                                          B Offline
                                          bibob
                                          wrote on sidst redigeret af
                                          #27

                                          God morgen. 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper